Antiproliferative activity and toxicity of 2-methoxyestradiol in cervical cancer xenograft mice

International Journal of Gynecological Cancer

Volumn 15, Issue 2, 2005, Pages 301-307

  Li, L ^a,b   Da, J ^c   Landstrom M ^d   Ulmsten, U ^a   Fu, X ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c AIR FORCE GENERAL HOSPITAL   (China)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

2 methoxyestradiol; Human cervical carcinoma; SCID mice

Indexed keywords

METHYLTESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CELL PROLIFERATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; HEART; HUMAN; HUMAN CELL; KIDNEY; KUPFFER CELL; LIQUEFACTION; LIVER; LIVER CELL; LUNG; MEGAKARYOCYTE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ANIMALS; ESTRADIOL; FEMALE; HELA CELLS; HUMANS; LIVER; MICE; MICE, SCID; PROLIFERATING CELL NUCLEAR ANTIGEN; SPLEEN; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 15444372332     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.15220.x     Document Type: Article

References (30)

1. Ferlay J, Bray P, Pisani P, Parkin DM. Globocan 2000. Cancer incidence, mortality and prevalence worldwide [book on CD-ROM]. Lyon: IARC Press; 2001.
2. Pisani P, Parkin DM, Bray F, Ferlay J Estimation of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
3. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997;14:379-84.
4. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999;5:493-9.
5. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000;89:983-94.
6. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 2002;187:77-86.
7. Djavaheri-Mergny M, Wietzerbin J, Besancon F. 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene 2003;22:2558-67.
8. Fotsis T, Zhang Y, Pepper MS et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
9. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
10. Arbiser JL, Panigrathy D, Klauber N et al. The anti-angiogenic agents TNP-470 and 2-methoxyestradiol inhibits the growth of angiosarcoma in mice. J Am Acad Dermatol 1999;40:925-9.
11. Kinuya S, Kawashima A, Yokoyama K et al. Anti-angiogenic therapy and adioimmunotherapy in colon cancer xenografts. Eur J Nucl Med 2001;28:1306-12.
12. Chauhan D, Catley L, Hideshima T et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002;100:2187-94.
13. Lippert TH, Adlercreutz H, Berger MR, Seeger H, Elger W, Mueck AO. Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma. J Steroid Biochem Mol Biol 2003;84:51-6.
14. 2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res 2004;24:873-80.
15. Josefsson E, Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 1997;40:154-63.
16. Kameyama K, Takami H, Umemura S et al. PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol 2000;7:301-4.
17. La Vallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002;62:3691-7.
18. Fotsis T, Zhang Y, Pepper MS et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
19. Dunn JF, Merriam GR, Eil C, Kono S, Loriaux DL, Nisula BC. Testosterone-estradiol binding globulin binds to 2-methoxyestradiol with greater affinity than to testosterone. J Clin Endocrinol Metab 1980;51:404-6.
20. Arbiser JL, Panigrathy D, Klauber N et al. The anti-angiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 1999;40:925-9.
21. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
22. Kinuya S, Kawashima A, Yokoyama K et al. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Eur J Nucl Med 2001;28:1306-12.
23. Huober JB, Nakamura S, Meyn R, Roth JA, Mukhopadhyay T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:1127-37.
24. Dingli D, Timm M, Russell SJ, Witzig TE, Rajkumar SV. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res 2002;8:3948-54.
25. Wassberg E. Angiostatic treatment of neuroblastoma. Ups J Med Sci 1999;104:1-24.
26. Qadan LR, Perez-Stable CM, Anderson C et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001;285:1259-66.
27. Banerjeei SK, Zoubine MN, Sarkar DK, Weston AP, Shah JH, Campbell DR. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. Anticancer Res 2000;20:2641-5.
28. 2) in patients (Pts) with refractory metastatic breast cancer (MBC). Paper presented at: 37th Annual Meeting of the American Society of Clinical Oncology; May 12-15, 2001; San Francisco, CA.
29. 2) plus docetaxel (D) in patients (pts) with metastatic breast cancer (MBC). Paper presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL.
30. Wilding G, Sweeney C, King DM et al. Phase 2, multicenter, randomized, double blind, safety, pharmacokinetic, pharmacodynamic and efficacy study of two doses of 2-methoxyestradiol administered orally in patients with hormone refractory prostate cancer. Paper presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL.